• FOLLOW US
Video Player
  • Email
  • share

Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs

Bristol-Myers Squibb's murky earnings report reveals a company still in flux. Earnings were slightly above analyst estimates at 48 cents a share. The company's revenue came in at $3.9 billion, down 4% from the same quarter last year. The sales declin

http://www.wltx.com/video/3695437586001/1/Bristol-Myers-Q2-Sales-Fall-Will-Focus-on-Cancer-Drugs http://cdn.newslook.com/c4/c4ad475ac4cd89e227bdfed3976a7f4e/images/frame_ext.jpg Bristol-Myers Q2 Sales Fall, Will Focus on Cancer Drugs Bristol-Myers Squibb's murky earnings report reveals a company still in flux. Earnings were slightly above analyst estimates at 48 cents a share. The company's revenue came in at $3.9 billion, down 4% from the same quarter last year. The sales declin theStreet.comTSCMNew YorkincFinanceAZNyoutubeYahoo!newslookastrazeneca plcbristol 00:50

Next Up

    

More Videos

Recent Videos

Page 1 of 7